-+ 0.00%
-+ 0.00%
-+ 0.00%

NATERA - TRIAL TO EVALUATE INCA33890 IN STAGE 2/3 CRC WITH SIGNATERA AS PRIMARY AND SECONDARY ENDPOINT

Reuters·11/10/2026 12:18:06